Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
The efficacy of transdermal scopolamine, oral meclizine, and placebo in protection against motion sickness was compared in a double-blind crossover study. Thirty-six healthy subjects were exposed to motion three times for 90 min in a ship-motion simulator. Transdermal applications were made and tablets were taken at least 12 and 2 hr before exposure to motion. Transdermal scopolamine provided better protection than placebo or meclizine. Dryness of mouth was the only side effect reported more frequently for one regimen, transdermal scopolamine.
D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008468:Meclizine / Q000009:adverse effects / Q000627:therapeutic use*; D009041:Motion Sickness / Q000517:prevention & control*; D012601:Scopolamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D008468:Meclizine; D012601:Scopolamine